Activation of the insulin-like growth factor-1 receptor (IGF-1R) is known to play a role in cardiomyocyte hypertrophy. While IGF-2R is understood to be a clearance receptor for IGF-2, there is also evidence that it may play a role in the induction of pathological cardiomyocyte hypertrophy. It is not known whether IGF-2R activates cardiomyocyte hypertrophy during growth of the fetal heart. Fetal sheep hearts (125 6 0.4 days gestation) were dissected, and the cardiomyocytes isolated from the left and right ventricles for culturing. Cultured cardiomyocytes were treated with either LONG R 3
INTRODUCTION
Left ventricular hypertrophy is the strongest predictor of progressive heart disease and poor cardiovascular outcomes in adult life [1, 2] . There is also evidence that poor growth before birth can result in left ventricular hypertrophy and in an increased incidence of cardiovascular disease in adult life [3] . Insulin-like growth factor 1 (IGF-1) has been implicated in the initiation of ventricular hypertrophy both in vitro and in vivo through the activation of IGF-1R and the recruitment of the downstream phosphoinositide 3-kinase (PI3-K) pathway [4, 5] . It has been shown that mice with enhanced cardiac PI3-K (p110a) signaling develop cardiac hypertrophy [6] . There are conflicting findings, however, on the role of IGF-1 in the induction of cardiomyocyte hypertrophy before birth. In the sheep in late gestation, neither in vitro culture of isolated cardiomyocytes with LONG R 3 IGF-1, to activate IGF-1R, nor intrafetal infusion of LONG R 3 IGF-1 (an IGF-1 analog that binds to IGF-binding protein with much lower affinity than endogenous IGF-1 [7] ) result in an increase in cardiomyocyte size [8] . In contrast, intrafetal infusion of IGF-1 in the sheep resulted in hypertrophy of cardiomyocytes in male fetuses only [9] . IGF-2 is also an important regulator of fetal growth [10] , and it has been shown that IGF-2 can act through the IGF-1R to induce cardiomyocyte growth in the fetus [8, 11] and to induce hypertrophy of neonatal and adult rat ventricular cardiomyocytes in vitro [12, 13] .
Interestingly, we have found that the induction of intrauterine growth restriction results in an increase in cardiac expression of IGF-2R in the heart of growth-restricted fetal sheep and postnatal lambs [14] . The role of IGF-2R in the mediation of fetal organ growth is generally understood to be through the clearance of IGF-2 via mannose-6-phosphate mediated targeting and lysosomal degradation [15] . It has recently been shown, however, that activation of the IGF-2R-signaling pathway in H9c2 cardiomyoblasts [16] and adult rat ventricular cardiomyocytes [17] directly results in an increase in cardiomyocyte size. One possibility is that IGF-2 may be able to stimulate cardiomyocyte hypertrophy not only through the IGF-1R signal transduction pathway, but also separately through an IGF-2R-signaling pathway. A recent series of studies in the rat has demonstrated that the latter pathway may be recruited when the IGF-1R pathway is inhibited [16] . A number of studies have found that specific activation of the IGF-2R-signaling pathway results in phosphorylation of protein kinase C-a (PKC-a) and Ca 2þ /calmodulin-dependent protein kinase II (CaMKII) [16] , which have been associated with increased cardiac synthesis of the natriuretic peptides, atrial natriuretic peptide (ANP) and brain-derived natriuretic peptide (BNP), and in pathological hypertrophy of the heart. Agonists of the IGF-2R-signaling pathway have been shown to induce cardiomyocyte hypertrophy [18, 19] . CaMKII, the extracellular signal-regulated protein kinase (ERK) and PKC are important components of the downstream signaling pathways for Gaq, and all three proteins have been implicated in cardiac hypertrophy in rodent models [20, 21] . Altered Gaq signaling and hypertrophic growth in the heart may have origins in fetal life [14] , accounting for the association between poor fetal growth, low birth weight, and an increased risk of cardiovascular disease in adult life [3, 22, 23] .
Neonatal rat cardiomyocytes are mononucleated and contribute to the growth of the heart predominantly through proliferation, becoming binucleated at between 7 and 11 days after birth [24] . Binucleated cardiomyocytes then contribute to the growth of the heart through hypertrophy [7] . This is in contrast to the human and sheep where the transition to binucleated cardiomyocytes, which undergo greater hypertrophy, begins in late gestation [10, 25] . Therefore, when considering the fetal origins of human heart disease, it is important to study the role of IGF-1R and IGF-2R in cardiomyocyte hypertrophy in a sheep model that has a similar cardiomyocyte maturation and hypertrophic process in utero. In the present study, we test the hypothesis that activation of the IGF-1R will increase the size of fetal sheep cardiomyocytes in vitro through activation of the ER-signaling pathway, whereas activation of the IGF-2R will increase the size of fetal sheep cardiomyocytes through activation of the CaMKII-, PKC-, and/ or ERK-signaling pathways.
MATERIALS AND METHODS

Animals and Postmortem Tissue Collection
All the procedures were approved by the University of South Australia Animal Ethics Committee. Six pregnant Merino ewes were used in this study. Ewes were humanely killed with an overdose of sodium pentobarbitone (25 ml of 325 mg/ml) into the maternal jugular vein at 125 6 0.4 days gestation (term, 150 6 3 days). Fetuses (n ¼ 9) were delivered by hysterotomy and then weighed. The fetal hearts were dissected, weighed, and perfused through the aorta with heparin and saturated KCl to prevent blood clotting and to arrest the heart in diastole, respectively [7, 11] .
Isolation of Cardiomyocytes and Cell Culture
The heart was suspended from a Langendorff apparatus via the aorta and cardiomyocytes isolated as previously described [11] . Cardiomyocytes from the left and right ventricles were isolated independently (left ventricle, 51.3 3 10 6 6 8.47 3 10 6 ; right ventricle, 41.6 3 10 6 6 6.51 3 10 6 ). The percentage of mononucleated cardiomyocytes was determined in a sample of 300 cardiomyocytes in each ventricle. There was a mix of mononucleated (right ventricle, 54.5% 6 2.4%; left ventricle, 55.0% 6 4.3%) and binucleated (right ventricle, 45.5% 6 4.3%; right ventricle, 45.0% 6 4.3%) cardiomyocytes. The protocol for culturing cardiomyocytes was adapted from a previous study [7] . Briefly, cells were centrifuged at 1328 3 g in a Sigma Centrifuge 10680 6K15 (Sigma Laboratory Centrifuges) for 3 min. The supernatant was removed and the cells resuspended at a concentration of 1 3 10 6 cells/ml in culture medium containing serum (1:1 Dulbecco modified Eagle medium [DMEM; catalog no. 12430054; Invitrogen]:Hams F12 [catalog no. 11765054; Invitrogen] salt solutions supplemented with 2 mM KCl, 0.2 mM glycine, 5 mM creatine, 5 mM taurine, 2 mM L-carnitine, 1% insulin-transferrin-sodium selenite medium supplement, 10% fetal calf serum, and 1:100 penicillin/streptomycin). Ten milliliters of cell suspension was added to a T 75 tissue culture flask for 2.5 h in a humidified incubator (378C, 5% CO 2 ) to preplate fibroblasts and endothelial cells. Nonadherent cells were removed from the tissue culture and replated for another 2.5 h. The nonadherent cells were removed and recentrifuged at 1328 3 g. The cardiomyocyte concentration was then determined (left ventricle, 7.8 3 10 6 6 0.97 3 10 6 ; right ventricle, 5.8 3 10 6 6 1.08 3 10 6 ) and the cells resuspended in serum-free culture medium (1:1 DMEM:Hams F12 salt solutions supplemented with 2 mM KCl, 0.2 mM glycine, 5 mM creatine, 5 mM taurine, 2 mM L-carnitine, 1% insulin-transferrin-sodium selenite medium supplement, and 1:100 penicillin/streptomycin) at 1 3 10 6 cardiomyocytes/ml and plated onto sterile 22 mm 3 22 mm coverslips (pretreated with 10 lg/ml laminin) in 6-well plates. Cardiomyocytes were cultured in serum-free culture medium with 4 3 10 5 cells per coverslip in a final volume of 2 ml per culture plate well and incubated for 24 h before drug treatment commenced.
Drugs and Experimental Protocols
Cardiomyocytes were incubated in various drug treatments with their respective sample size and concentration indicated in Table 1 . Serum-free media was replaced with either 2 ml of fresh serum-free media (control), 2 ml of media with serum (positive control; to increase cardiomyocyte size), 2 ml of serum-free media containing a vehicle with which experimental drugs were reconstituted (negative control), or 2 ml of serum-free media containing agonists and/or antagonists of the IGF-1R and/or IGF-2R signaling pathways for 48 h. For cardiomyocytes that were exposed to both an inhibitor and agonist, the inhibitor was added 30 min prior to the addition of the agonist.
Media was removed, and the cardiomyocytes were fixed with 70% ethanol in 50 mM glycine at À208C for 30 min. After fixation, the ethanol was aspirated, and the cardiomyocytes were washed with PBS and then stored in PBS containing 1% sodium azide at 48C.
Cardiomyocyte Cross-Sectional Area Measurements
Cardiomyocytes were treated with 3% hydrogen peroxide for 10 min to remove endogenous peroxidase activity. Cardiomyocytes were incubated on slides with anti-myosin, ventricular heavy chain a/b antibody (1:100; Millipore) for 1 h at room temperature. A Histostain-Plus (HRP-broad spectrum) kit (Invitrogen Australia Pty Limited) was used with 3,3-diaminobenzidine (DAB) (Metal Enhanced DAB Substrate Kit, Pierce Biotechnology) to visualize and identify the cardiomyocytes [7] . Cells were counterstained with Mayer haemotoxylin (Sigma Aldrich) to determine nucleation and then dehydrated before the coverslips with the cells fixed to them were mounted in a xylene-based medium on a glass slide. To determine the effect of each treatment on cell size, the area of 50 mononucleated and 50 binucleated cardiomyocytes were determined on each slide and the average (one slide for each treatment) was used to represent the size of cardiomyocytes in that ventricle for that animal using AnalySIS software (Software Imaging System). All the cardiomyocyte cross-sectional area measures were performed by an individual who was blind with respect to the animal, ventricle, and drug treatment being assessed.
Data and Statistical Analysis
All the measurements of cardiomyocyte cross-sectional area were expressed relative to the respective control group that had been cultured in serum-free media. Multiple comparisons were tested with two-way ANOVA with the factors being treatment and ventricle (SPSS 18 for Windows, Statistical Package for Social Scientists Inc.). The data from the left and right ventricles were combined because there was no interaction between the treatment and ventricle. If there was a significant effect of treatment, Duncan post hoc tests were performed to determine which treatments were different. Sample sizes for drug treatments are reported and represent the number of animals treated. Data are presented as the mean 6 SEM, and P , 0.05 is considered statistically significant.
RESULTS
Activation of IGF-1R or IGF-2R and the Impact on the Area of Mononucleated Cardiomyocytes
Cardiomyocytes that had been cultured in serum-free culture medium were used as an untreated control in each experiment. There was an effect of serum but not LONG R 3 IGF-1 (P ¼ 0.048; Fig. 1A ) or Leu 27 IGF-2 (P ¼ 0.031; Fig. 1B ) on the size of mononucleated cardiomyocytes. There was no effect of the vehicle solutions, acetic acid or dimethyl sulfoxide (DMSO), on the size of mononucleated cardiomyocytes (data not shown).
Activation of IGF-1R and the Impact on the Area of Binucleated Cardiomyocytes
Neither acetic acid (n ¼ 6) nor DMSO (n ¼ 6) resulted in a change in the cross-sectional area of the binucleated cardiomyocytes when compared to control cardiomyocytes cultured in serum-free medium (data not shown). Cardiomyocytes cultured in the presence of serum had an increased cross-sectional area when compared to the controls (P , 0.001; WANG ET AL. Fig. 2; Supplemental Fig. S1, A and B , all the supplemental data are available online at www.biolreprod.org). The activation of the IGF-1R with LONG R 3 IGF-1 resulted in an increase in the area of binucleated cardiomyocytes compared to controls. This effect was abolished when the cardiomyocytes were cocultured with either the IGF-1R inhibitor, picropodophyllin (PPP) [8, 12] , and/or the MEK 1/2 inhibitor, U0126, which blocks phosphorylation and activation of ERK [13] (Fig.  2) .
Increased Cross-Sectional Area of Binucleated Cardiomyocytes Following Activation of the IGF-2R Involves CaMKII and ERK Signaling Leu 27 IGF-2 treatment increased the cross-sectional area of binucleated cardiomyocytes relative to controls (P , 0.001; Fig. 3 and Supplemental Fig. S1C ). The CaMKII inhibitor, KN-93, prevented the Leu 27 IGF-2 induced increase in cardiomyocyte cross-sectional area (Supplemental Fig. S1D ).
KN-92 or Gö6976 treatment, however, did not prevent the Leu 27 IGF-2 induced increase in cardiomyocyte cross-sectional area. U0126, a MEK 1/2 inhibitor, blocked the Leu 27 IGF-2 induced increase in cardiomyocyte size (P ¼ 0.001; Fig. 4 ).
DISCUSSION
Activation of the IGF-1R-signaling pathway results in hypertrophy of binucleated cardiomyocytes from the sheep fetus, and this effect is dependent on ERK signaling. In contrast to the general view that IGF-2R acts as a clearance receptor to limit the effects of IGF-2 on IGF-1R, we have demonstrated that IGF-2R activation also resulted in hypertrophy of cardiomyocytes from the sheep fetus. This effect was dependent both on ERK signaling and on CaMKII, but not PKC or activation of L-type calcium channels. IGF-2R can bind to Gaq-coupled receptors [16] , and activation of Gaq initiates a number of downstream signaling pathways, including CaMKII, ERK, and the PKC family (Fig. 5) Inhibitor of both MEK1 and MEK2, which blocks the phosphorylation and activation of ERK [13] 10 lM Sigma Aldrich 5 5
To IGF-2R SIGNALING AND CARDIOMYOCYTE HYPERTROPHY hypertrophy [1] . The present study was therefore carried out to investigate whether IGF-1R and IGF-2R can each activate downstream signaling pathways to result in hypertrophy of cultured cardiomyocytes from the fetal sheep heart.
Hypertrophy of Binucleated but Not Mononucleated Cardiomyocytes
During the second half of gestation in the sheep, it has been shown that both mononucleated and binucleated cardiomyocytes increase in area [27] although to a lesser extent than mononucleated cardiomyocytes [25, 28] . Studies have shown that phenylephrine acts to increase the area of cultured binucleated, but not mononucleated, cardiomyocytes from the late gestation sheep fetus [7] . These data support our finding that activation of the IGF-1R and IGF-2R signaling pathways increased cardiomyocyte size in only binucleated, not mononucleated, cardiomyocytes.
The IGF-1R and Cardiomyocyte Hypertrophy
IGF-1 gene expression is increased in the adult rat heart in experimental models of cardiac hypertrophy [4] [5] [6] 29] . IGF-1 is an important fetal growth factor and plays a critical role in the maturation and growth of the fetal heart [5] . In the sheep, intrafetal IGF-1 infusion increases cardiomyocyte volume but only in male fetuses [9] . In the present study, LONG R 3 IGF-1 acted in vitro to increase the area of cultured binucleated, but not mononucleated, cardiomyocytes isolated from fetal sheep at 125 6 0.4 days of gestation, and this effect was blocked by the IGF-1R autophosphorylation inhibitor, PPP. The inhibitor of MEK1/ 2, U0126, also blocked the hypertrophic actions of LONG R 3 IGF-1, confirming that ERK signaling plays a role in the IGF-1R-mediated hypertrophy of the binucleated cardiomyocytes. While these findings are consistent with the in vivo study in sheep reported above and a prior study in the adult rat [30] , there are conflicting data in the literature on the effects of activation of the IGF-1 pathway on cardiomyocyte growth. Studies in the sheep using either intrafetal LONG R 3 IGF-1 infusion for 7 days or culturing fetal sheep cardiomyocytes with LONG R 3 IGF-1 found that these treatments did not cause cardiomyocyte hypertrophy, but rather resulted in an increase in cardiomyocyte proliferation that was dependent on both ERK (downstream target of Ras/Raf-1) [31] and PI3-K [7] . This suggests that stimulation of IGF-1R can activate different mechanisms resulting in either cardiomyocyte proliferation or hypertrophy. The nature of the pathways activated and the final phenotypic response may be dependent on gestational age, timing or length of IGF-1 exposure, the nucleation of the cardiomyocytes at the time of exposure, and/or other binding proteins present within the fetal cardiac tissue. It does appear from the present study, however, that the hypertrophic response of cardiomyocytes to IGF-1R stimulation is dependent upon ERK signaling in conjunction with the PI3-K-Akt-p70S6K1-signaling pathway [5] .
IGF-2R-Gaq Signaling and Cardiomyocyte Hypertrophy
Gaq signaling has been identified as an important factor in cardiac hypertrophy [32] . Transgenic mice with cardiac specific Gaq overexpression have a hypertrophic cardiac phenotype; defined by increased ANP and BNP gene expression, increased heart weight in relation to body weight and increased cardiomyocyte size [32] . Our study showed that treatment with the IGF-2R agonist, Leu 27 IGF-2, resulted in an increase in the cross-sectional area of the binucleated, but not mononucleated, cardiomyocytes. This is consistent with a previous report of increased rat H9c2 cardiomyoblast size after treatment with Leu 27 IGF-2 [16] and indicates a role for IGF-2R-Gaq signaling in cardiomyocyte hypertrophy. Leu 27 IGF-2 treatment increased expression of the phosphorylated form of PKC-a and CaMKII, but not ERK1/2, while knockdown of Gaq inhibited Leu 27 IGF-2-induced PKC-a and CaMKII activation [16] . Importantly, this signaling pathway has been implicated in pathological cardiac hypertrophy [16] .
The Role of PKC Signaling in Cardiomyocyte Hypertrophy
PKC has several isoforms but is known to mediate cardiomyocyte hypertrophy in both neonatal and adult rats through the ERK-signaling pathway. PKC-a-induced cardiac hypertrophy was shown to be associated with an increase in protein synthesis and thus protein-to-DNA ratio, but not with an increase in cardiomyocyte area under basal conditions [27] . There was also no reduction in cardiac hypertrophy associated with pressure overload in transgenic mice lacking PKC-a [28] . PKC-b expression is not essential for the development of cardiac hypertrophy because in the absence of PKC-b, there IGF-2R SIGNALING AND CARDIOMYOCYTE HYPERTROPHY was no hypertrophy in response to pharmacological stimuli or pressure overload [33] . In some models, hypertension and marked cardiac hypertrophy is independent of either PKC-a or PKC-c protein expression [34] . Given the conflicting results regarding the role of PKC in cardiac hypertrophy, it has been suggested that PKC proteins are either not primary regulators of hypertrophy or that there is gene redundancy in vivo [35] . We have found in the present study that in cardiomyocytes from the sheep fetus, which had been stimulated to undergo hypertrophy with Leu 27 IGF-2, Gö6976 inhibition of PKC did not alter the hypertrophic response. This suggests that PKC does not serve as a downstream element of the IGF-2R hypertrophic response in the fetal heart.
Activation of L-Type Calcium Channels and Cardiomyocyte Hypertrophy
In the current study, we used KN-93 to inhibit CaMKII, but this inhibitor may also act on L-type calcium channels [36] ; activation of these channels has been associated with cardiac hypertrophy [37] . KN-92, which inhibits L-type calcium channels [38] but not the CaM kinase family, did not prevent the hypertrophic effect of area of Leu 27 IGF-2 on binucleated cardiomyocytes, but did not abrogate this effect. This finding is consistent with the conclusion from an in vitro study of adult rat cardiomyocytes that showed that cardiomyocyte hypertrophy induced by both IGF-1 and IGF-2 was dependent on activation of L-type calcium channels [39] .
CaMKII Signaling and Cardiomyocyte Hypertrophy
There is emerging evidence for a role of CaMKII in pathological cardiac hypertrophy and heart failure [40, 41] . CaMKII activation of cardiac hypertrophy has also been reported either in spontaneously hypertensive rats following pressure overload in CaMKII transgenic mice or in response to CaMKII genetic inhibition [21, 41, 42] . In cultured neonatal rat ventricular myocytes, phenylephrine-induced ANP gene expression and myofilament reorganization were each blocked by the CaMKII inhibitor KN-93 [43] . Based on in vivo and in vitro evidence, CaMKII activation is both necessary and sufficient for the induction of cardiac hypertrophy [35] . In cultured cardiomyocytes from the sheep fetus, we have shown that CaMKII signaling mediates IGF-2R-induced hypertrophy of the binucleated cardiomyocytes. As CaMKII enhances ERK signaling by facilitating assembly of the Raf/MEK/ERK complex, we have also investigated the role of ERK signaling in IGF-2R-mediated cardiomyocyte hypertrophy [44, 45] .
Role of ERK in IGF-2R-Mediated Cardiomyocyte Hypertrophy
The ERK pathway is essential for the hypertrophic response of cardiomyocytes to endothelin-1 and phenylephrine [46] , and cardiac hypertrophy induced by pressure overload is associated with an upregulation of ERK signaling through both Gaq-and non-Gaq-signaling pathways [47] . In the present study, ERK inhibition with U0126 blocked Leu 27 IGF-2-induced cardiomyocyte hypertrophy; we also demonstrated a role for ERK signaling in cardiomyocyte hypertrophy induced by either IGF-1R or IGF-2R activation. Interestingly, IGF-1 can activate ERK in the absence of a functional IGF-1R tyrosine kinase in smooth muscle cells, possibly through actions on Gai or Gbc [48] . IGF-1R inhibition has been shown to upregulate local IGF-2 synthesis to result in an increase in cardiomyocyte size [17, 49] . In the present studies, however, because we specifically activated the IGF-1R with LONG R 3 IGF-1, the activation of ERK was most likely mediated directly through IGF-1R. It is possible in the developing heart in vivo that there may be crosstalk between the IGF-1R-and IGF-2R-signaling pathways influencing ERK.
In conclusion, we have demonstrated that in cardiomyocytes from the sheep fetus, in vitro activation of either the IGF-1R or the IGF-2R leads to an increase in the cross-sectional area of binucleated cardiomyocytes. The IGF-1R-mediated ERK signaling pathway and the IGF-2R-mediated CaMKII-and ERK-signaling pathways were important in the induction of the cardiomyocyte hypertrophy. The CaMKII-and ERK-signaling pathways in cardiomyocytes (Fig. 5) may play a role in inducing ventricular hypertrophy when IGF-2R expression is increased.
